Ovid Historical Balance Sheet

OVID Stock

USD 0.43 0.01 2.27%

Trend analysis of Ovid Therapeutics balance sheet accounts such as Net Tangible Assets of 81.7 M provides information on Ovid Therapeutics' total assets, liabilities, and equity, which is the actual value of Ovid Therapeutics to its prevalent stockholders. By breaking down trends over time using Ovid Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Ovid Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ovid Therapeutics is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.

About Ovid Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Ovid Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Ovid Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Ovid Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Ovid currently owns. An asset can also be divided into two categories, current and non-current.

Ovid Therapeutics Balance Sheet Chart

At present, Ovid Therapeutics' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Accounts Payable is expected to grow to about 3.2 M, whereas Net Tangible Assets are forecasted to decline to about 81.7 M.

Total Assets Total Current Liabilities Total Stockholder Equity Net Tangible Assets Preferred Stock Total Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Ovid Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Ovid Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Ovid Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Ovid Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most accounts from Ovid Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Ovid Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.At present, Ovid Therapeutics' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Accounts Payable is expected to grow to about 3.2 M, whereas Net Tangible Assets are forecasted to decline to about 81.7 M.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	7.0M	11.5M	10.5M	9.7M
Total Assets	155.3M	144.0M	92.2M	100.8M

Total Current Liabilities Total Assets

Ovid Therapeutics balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Common Stock Shares Outstanding	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Other Current Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Other Current Assets	Other Stockholder Equity	Property Plant And Equipment Gross	Preferred Stock Total Equity
Total Assets		0.68	0.97	0.94	-0.71	0.77	0.81	0.44	0.87	0.66	0.98	0.57	0.8	0.59	0.55	0.55	-0.35	0.53	0.67	0.77	0.32	0.83	0.76	0.85	0.55	-0.76
Total Current Liabilities	0.68		0.58	0.59	-0.86	0.93	0.51	0.26	0.79	0.72	0.67	0.78	0.8	0.37	0.98	0.27	-0.07	0.34	0.56	0.35	0.38	0.82	0.83	0.85	0.28	-0.82
Total Stockholder Equity	0.97	0.58		0.92	-0.58	0.71	0.88	0.51	0.77	0.47	0.98	0.52	0.69	0.48	0.44	0.44	-0.49	0.41	0.61	0.81	0.32	0.72	0.63	0.74	0.44	-0.69
Net Tangible Assets	0.94	0.59	0.92		-0.7	0.7	0.7	0.36	0.87	0.63	0.88	0.49	0.79	0.66	0.44	0.61	-0.26	0.62	0.7	0.66	0.29	0.84	0.74	0.83	0.61	-0.72
Retained Earnings	-0.71	-0.86	-0.58	-0.7		-0.77	-0.32	-0.18	-0.9	-0.83	-0.63	-0.77	-0.89	-0.75	-0.82	-0.68	-0.22	-0.73	-0.7	-0.27	-0.46	-0.92	-0.92	-0.95	-0.69	0.9
Accounts Payable	0.77	0.93	0.71	0.7	-0.77		0.64	0.45	0.78	0.62	0.78	0.77	0.77	0.33	0.86	0.22	-0.26	0.3	0.68	0.54	0.41	0.79	0.84	0.82	0.23	-0.83
Cash	0.81	0.51	0.88	0.7	-0.32	0.64		0.6	0.55	0.21	0.88	0.4	0.48	0.1	0.4	0.08	-0.77	0.0	0.41	0.78	0.15	0.51	0.39	0.52	0.07	-0.49
Other Assets	0.44	0.26	0.51	0.36	-0.18	0.45	0.6		0.26	0.02	0.48	0.55	0.2	0.0	0.14	0.0	-0.42	-0.06	0.7	0.35	0.35	0.23	0.4	0.29	-0.01	-0.46
Common Stock Shares Outstanding	0.87	0.79	0.77	0.87	-0.9	0.78	0.55	0.26		0.84	0.79	0.63	0.97	0.76	0.71	0.71	-0.09	0.71	0.7	0.55	0.24	0.98	0.88	0.97	0.72	-0.8
Total Liab	0.66	0.72	0.47	0.63	-0.83	0.62	0.21	0.02	0.84		0.56	0.48	0.82	0.69	0.67	0.69	0.25	0.7	0.58	0.32	0.16	0.81	0.85	0.83	0.69	-0.68
Total Current Assets	0.98	0.67	0.98	0.88	-0.63	0.78	0.88	0.48	0.79	0.56		0.57	0.72	0.44	0.55	0.4	-0.46	0.38	0.6	0.81	0.33	0.74	0.69	0.77	0.4	-0.72
Intangible Assets	0.57	0.78	0.52	0.49	-0.77	0.77	0.4	0.55	0.63	0.48	0.57		0.66	0.3	0.75	0.24	0.07	0.27	0.66	0.19	0.77	0.69	0.77	0.74	0.24	-0.85
Common Stock	0.8	0.8	0.69	0.79	-0.89	0.77	0.48	0.2	0.97	0.82	0.72	0.66		0.7	0.75	0.66	-0.1	0.65	0.63	0.56	0.32	0.99	0.86	0.97	0.66	-0.8
Property Plant Equipment	0.59	0.37	0.48	0.66	-0.75	0.33	0.1	0.0	0.76	0.69	0.44	0.3	0.7		0.3	0.98	0.29	0.99	0.61	0.28	0.11	0.71	0.66	0.72	0.98	-0.58
Other Current Liab	0.55	0.98	0.44	0.44	-0.82	0.86	0.4	0.14	0.71	0.67	0.55	0.75	0.75	0.3		0.21	-0.02	0.27	0.42	0.27	0.36	0.76	0.75	0.78	0.22	-0.75
Property Plant And Equipment Net	0.55	0.27	0.44	0.61	-0.68	0.22	0.08	0.0	0.71	0.69	0.4	0.24	0.66	0.98	0.21		0.3	0.96	0.58	0.27	0.07	0.66	0.61	0.67	1.0	-0.51
Net Debt	-0.35	-0.07	-0.49	-0.26	-0.22	-0.26	-0.77	-0.42	-0.09	0.25	-0.46	0.07	-0.1	0.29	-0.02	0.3		0.39	0.03	-0.73	0.18	-0.06	0.11	-0.04	0.3	-0.01
Non Current Assets Total	0.53	0.34	0.41	0.62	-0.73	0.3	0.0	-0.06	0.71	0.7	0.38	0.27	0.65	0.99	0.27	0.96	0.39		0.61	0.21	0.11	0.66	0.66	0.68	0.97	-0.55
Non Currrent Assets Other	0.67	0.56	0.61	0.7	-0.7	0.68	0.41	0.7	0.7	0.58	0.6	0.66	0.63	0.61	0.42	0.58	0.03	0.61		0.31	0.37	0.67	0.86	0.73	0.58	-0.79
Cash And Short Term Investments	0.77	0.35	0.81	0.66	-0.27	0.54	0.78	0.35	0.55	0.32	0.81	0.19	0.56	0.28	0.27	0.27	-0.73	0.21	0.31		0.05	0.5	0.38	0.51	0.26	-0.39
Net Receivables	0.32	0.38	0.32	0.29	-0.46	0.41	0.15	0.35	0.24	0.16	0.33	0.77	0.32	0.11	0.36	0.07	0.18	0.11	0.37	0.05		0.36	0.47	0.42	0.07	-0.67
Common Stock Total Equity	0.83	0.82	0.72	0.84	-0.92	0.79	0.51	0.23	0.98	0.81	0.74	0.69	0.99	0.71	0.76	0.66	-0.06	0.66	0.67	0.5	0.36		0.88	0.99	0.66	-0.84
Other Current Assets	0.76	0.83	0.63	0.74	-0.92	0.84	0.39	0.4	0.88	0.85	0.69	0.77	0.86	0.66	0.75	0.61	0.11	0.66	0.86	0.38	0.47	0.88		0.93	0.62	-0.93
Other Stockholder Equity	0.85	0.85	0.74	0.83	-0.95	0.82	0.52	0.29	0.97	0.83	0.77	0.74	0.97	0.72	0.78	0.67	-0.04	0.68	0.73	0.51	0.42	0.99	0.93		0.67	-0.9
Property Plant And Equipment Gross	0.55	0.28	0.44	0.61	-0.69	0.23	0.07	-0.01	0.72	0.69	0.4	0.24	0.66	0.98	0.22	1.0	0.3	0.97	0.58	0.26	0.07	0.66	0.62	0.67		-0.52
Preferred Stock Total Equity	-0.76	-0.82	-0.69	-0.72	0.9	-0.83	-0.49	-0.46	-0.8	-0.68	-0.72	-0.85	-0.8	-0.58	-0.75	-0.51	-0.01	-0.55	-0.79	-0.39	-0.67	-0.84	-0.93	-0.9	-0.52

Click cells to compare fundamentals

Ovid Therapeutics Account Relationship Matchups

Ovid Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	75.9M	194.5M	155.3M	144.0M	92.2M	100.8M
Total Current Liabilities	22.1M	14.8M	7.0M	11.5M	10.5M	9.7M
Total Stockholder Equity	43.6M	179.7M	132.3M	87.8M	68.2M	82.6M
Net Tangible Assets	69.6M	43.3M	179.7M	132.3M	152.1M	81.7M
Retained Earnings	(294.2M)	(171.4M)	(225.5M)	(277.9M)	(304.3M)	(289.1M)
Accounts Payable	5.4M	7.1M	2.0M	3.7M	3.2M	3.2M
Cash	72.0M	187.8M	129.0M	27.0M	26.3M	25.0M
Other Assets	(100.0)	2.0M	1.9M	1.0	1.15	1.09
Common Stock Shares Outstanding	58.5M	68.1M	70.4M	70.6M	70.9M	47.1M
Total Liab	32.3M	14.8M	23.0M	56.2M	23.9M	18.2M
Total Current Assets	74.8M	190.5M	131.4M	109.6M	55.9M	90.2M
Intangible Assets	318.9K	260.1K	261.2K	183.0K	210.4K	235.2K
Common Stock	65.7K	70.4K	70.5K	70.7K	71K	50.2K
Property Plant Equipment	68.4K	135.6K	242.8K	1.1M	1.3M	1.4M
Other Current Liab	14.4M	7.7M	4.5M	6.5M	6.0M	6.6M
Property Plant And Equipment Net	135.6K	242.8K	16.1M	14.7M	13.2M	13.9M
Net Debt	(72.0M)	(187.8M)	(112.5M)	(11.0M)	(25.0M)	(26.2M)
Non Current Assets Total	1.1M	4.1M	23.9M	34.4M	36.2M	38.0M
Non Currrent Assets Other	627.8K	1.9M	2.0M	2.0M	2.0M	1.5M
Cash And Short Term Investments	72.0M	187.8M	129.0M	105.8M	53.1M	96.2M
Common Stock Total Equity	54.7K	65.7K	70.4K	70.5K	81.0K	46.7K
Liabilities And Stockholders Equity	75.9M	194.5M	155.3M	144.0M	92.2M	110.4M
Other Current Assets	2.7M	2.7M	2.4M	3.8M	2.9M	2.3M
Other Stockholder Equity	337.8M	351.0M	357.8M	365.6M	372.5M	290.0M
Property Plant And Equipment Gross	135.6K	505.0K	16.7M	15.7M	14.6M	15.4M
Accumulated Other Comprehensive Income	(1.8K)	2.5K	(42.2K)	702.0	(35K)	(33.3K)
Non Current Liabilities Total	10.2M	7.1M	16.0M	44.8M	13.4M	11.2M
Retained Earnings Total Equity	(213.2M)	(294.2M)	(171.4M)	(225.5M)	(203.0M)	(213.1M)
Capital Surpluse	283.1M	337.8M	351.0M	357.8M	411.4M	312.6M
Net Invested Capital	43.6M	179.7M	132.3M	87.8M	68.2M	96.8M
Net Working Capital	52.8M	175.7M	124.4M	98.1M	45.4M	43.1M
Capital Stock	65.7K	70.4K	70.5K	70.7K	71K	67.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:

How To Invest In Ovid

Details

Is Ovid Stock a good investment?

Details

What is Ovid Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.37)

Revenue Per Share

0.008

Quarterly Revenue Growth

(0.47)

Return On Assets

(0.31)

Return On Equity

(0.34)

The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ovid Historical Balance Sheet

About Ovid Balance Sheet Analysis

Ovid Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Net Tangible Assets

Ovid Therapeutics balance sheet Correlations

Ovid Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ovid Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Common Stock Total Equity	+ 0.99	Common Stock
Non Current Assets Total	+ 0.99	Property Plant Equipment
Other Stockholder Equity	+ 0.99	Common Stock Total Equity
Total Current Assets	+ 0.98	Total Assets
Other Current Liab	+ 0.98	Total Current Liabilities

Other Stockholder Equity	- 0.95	Retained Earnings
Preferred Stock Total Equity	- 0.93	Other Current Assets
Other Current Assets	- 0.92	Retained Earnings
Common Stock Total Equity	- 0.92	Retained Earnings
Preferred Stock Total Equity	- 0.9	Other Stockholder Equity
Common Stock Shares Outstanding	- 0.9	Retained Earnings